Department of Thoracic Surgery, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, China.
Department of Thoracic Surgery, Zhejiang Hospital, Hangzhou, China.
J Recept Signal Transduct Res. 2021 Oct;41(5):504-510. doi: 10.1080/10799893.2020.1828916. Epub 2020 Oct 1.
Cell division control (CDC) 42 has been involved in the regulation of diverse cancers. Macrophage recruitment plays an important role in the pathogenesis and development of tumor. However, it remains unclear whether CDC42 contributes to macrophage recruitment and lung tumorigenesis .
Small interference RNA (siRNA) was used to knock down CDC42 in the Lewis lung carcinoma (LLC)1. The invasion capability of CDC42 knockdown LLC1 cells was evaluated. LLC1 cells with CDC42 targeted small hairpin RNA (shRNA) were inoculated into C57BL/6 mice to establish the tumor-bearing animal model Tumor size and metastasis related proteins were measured. In addition, the invasion of macrophages in the tumor site as well as macrophage chemokine were also determined in the model.
The capacity of invasion and metastasis of LLC1 cells significantly decreased when CDC42 was knocked down. When inoculated with CDC42 knockdown LLC1 cells , the tumor size and metastasis related proteins levels both decreased. The invasion capacity of macrophages and the associated macrophage chemokine were also significantly down-regulated.
Our data suggest that the inhibition of CDC42 expression in lung cancer cells can significantly prevent the pathogenesis and development of tumor in an allograft tumor model , which might provide a novel therapeutic target and potential strategy for lung cancer treatment in the future.
细胞分裂控制蛋白 42(CDC42)参与了多种癌症的调控。巨噬细胞募集在肿瘤的发病机制和发展中起着重要作用。然而,CDC42 是否有助于巨噬细胞募集和肺癌发生仍不清楚。
使用小干扰 RNA(siRNA)敲低 Lewis 肺癌(LLC)1 中的 CDC42。评估敲低 CDC42 的 LLC1 细胞的侵袭能力。将靶向 CDC42 的短发夹 RNA(shRNA)的 LLC1 细胞接种到 C57BL/6 小鼠中建立荷瘤动物模型,测量肿瘤大小和转移相关蛋白。此外,还在模型中测定肿瘤部位巨噬细胞的侵袭以及巨噬细胞趋化因子。
当敲低 CDC42 时, LLC1 细胞的侵袭和转移能力显著降低。当接种敲低 CDC42 的 LLC1 细胞时,肿瘤大小和转移相关蛋白水平均降低。巨噬细胞的侵袭能力和相关的巨噬细胞趋化因子也显著下调。
我们的数据表明,抑制肺癌细胞中 CDC42 的表达可以显著阻止同种异体肿瘤模型中肿瘤的发病机制和发展,这可能为未来的肺癌治疗提供新的治疗靶点和潜在策略。